Literature DB >> 16010773

Use of a remifentanil and propofol combination in outpatients to facilitate rapid discharge home.

William J Brady1, Daniel R Meenan, Tirunellai R Shankar, Jennifer A Balon, Deanna R Mennett.   

Abstract

The goal of our study was to evaluate whether the combination of remifentanil and propofol facilitated shorter recovery time and decreased charges compared with conventional balanced anesthesia. We studied 49 patients, aged 13 to 75 years, who underwent elective outpatient surgery. All data were analyzed using the Pearson chi2 and the Student t test; results were considered statistically significant at a P value of.05 or less. Group 1 received a remifentanil-propofol combination and group 2, a conventional balanced anesthetic. Group 1 had decreased mean operating room (dollar 280.83 vs dollar 337.42; P = .05) and operating room plus postanesthesia care unit (PACU) (dollar 442.67 vs dollar 544.62) charges (P = .02). Group 1 had less PACU time (48.26 vs 59.62 minutes) and 2 group 1 patients bypassed the PACU. We conclude that a remifentanil-propofol combination is more cost effective than conventional balanced anesthetics and enables some patients to bypass the PACU, resulting in quicker discharge. Our findings have important implications for ambulatory surgery centers and office-based practices.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16010773

Source DB:  PubMed          Journal:  AANA J        ISSN: 0094-6354


  2 in total

1.  Comparison of propofol-remifentanil versus propofol-ketamine deep sedation for third molar surgery.

Authors:  Kyle J Kramer; Steven Ganzberg; Simon Prior; Robert G Rashid
Journal:  Anesth Prog       Date:  2012

2.  The effect of concentration, reconstitution solution and pH on the stability of a remifentanil hydrochloride and propofol admixture for simultaneous co-infusion.

Authors:  Emily Henkel; Rebecca Vella; Kieran Behan; David Austin; Peter Kruger; Andrew Fenning
Journal:  BMC Anesthesiol       Date:  2020-11-12       Impact factor: 2.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.